TipRanks
Advertisement
Advertisement

DE:DP8 Stock Latest News

CervoMed Advances Neflamapimod Tablet and Dosing Strategy
Company AnnouncementsCervoMed Advances Neflamapimod Tablet and Dosing Strategy
4d ago
8K
CRVO
CervoMed: Improved Dosing, Safety Margin and CMC Profile Bolster Confidence in 100 mg BID Regimen; Buy Rating and $12 Price Target Reiterated
PremiumRatings
CervoMed: Improved Dosing, Safety Margin and CMC Profile Bolster Confidence in 100 mg BID Regimen; Buy Rating and $12 Price Target Reiterated
5d ago
CRVO
CervoMed neflamapimod update removes key overhang, says Jones
PremiumThe Fly
CervoMed neflamapimod update removes key overhang, says Jones
5d ago
CRVO
CervoMed announces PK results with new neflamapimod oral tablet formula
PremiumThe Fly
CervoMed announces PK results with new neflamapimod oral tablet formula
5d ago
CRVO
CervoMed highlights late-breaking neflamapimod Phase 2a data
PremiumCompany Announcements
CervoMed highlights late-breaking neflamapimod Phase 2a data
22d ago
8K
CRVO
CervoMed price target lowered to $7 from $9 at Roth Capital
PremiumThe FlyCervoMed price target lowered to $7 from $9 at Roth Capital
1M ago
CRVO
CervoMed: Buy Rating Reiterated as Dementia Pipeline Advances; $25 Price Target Maintained
Premium
Ratings
CervoMed: Buy Rating Reiterated as Dementia Pipeline Advances; $25 Price Target Maintained
2M ago
CRVO
Analyst Maintains Buy on CervoMed, Cuts Target to $12 Amid Updated Launch Assumptions but Sees $3B Peak Sales Potential
Premium
Ratings
Analyst Maintains Buy on CervoMed, Cuts Target to $12 Amid Updated Launch Assumptions but Sees $3B Peak Sales Potential
2M ago
CRVO
CervoMed price target lowered to $18 from $27 at Canaccord
PremiumThe Fly
CervoMed price target lowered to $18 from $27 at Canaccord
2M ago
CRVO
CervoMed’s neflamapimod gains UK Innovation Passport
PremiumCompany Announcements
CervoMed’s neflamapimod gains UK Innovation Passport
2M ago
8K
CRVO
CervoMed advances neflamapimod strategy with new DLB data
PremiumCompany Announcements
CervoMed advances neflamapimod strategy with new DLB data
3M ago
8K
CRVO
CervoMed Completes Enrollment in Phase 2a Neflamapimod Trial
PremiumCompany Announcements
CervoMed Completes Enrollment in Phase 2a Neflamapimod Trial
3M ago
8K
CRVO
CervoMed completes enrollment in neflamapimod study
PremiumThe FlyCervoMed completes enrollment in neflamapimod study
3M ago
CRVO
CervoMed registers to sell 10.08M shares of common stock for holders
Premium
The Fly
CervoMed registers to sell 10.08M shares of common stock for holders
3M ago
CRVO
CervoMed Raises $10 Million in Direct Offering
Premium
Company Announcements
CervoMed Raises $10 Million in Direct Offering
3M ago
8K
CRVO
CervoMed announces $10M registered direct offering priced at-the-market
PremiumThe Fly
CervoMed announces $10M registered direct offering priced at-the-market
4M ago
CRVO
CervoMed Gains New Patent for Neflamapimod Dementia Therapy
PremiumCompany Announcements
CervoMed Gains New Patent for Neflamapimod Dementia Therapy
4M ago
8K
CRVO
CervoMed receives notice of allowance from USPTO on neflamapimod
PremiumThe Fly
CervoMed receives notice of allowance from USPTO on neflamapimod
4M ago
CRVO
CervoMed Posts Updated Investor Presentation and Business Overview
PremiumCompany Announcements
CervoMed Posts Updated Investor Presentation and Business Overview
4M ago
8K
CRVO
CervoMed Announces Private Placement to Advance Neurology Pipeline
PremiumCompany AnnouncementsCervoMed Announces Private Placement to Advance Neurology Pipeline
4M ago
8K
CRVO
CervoMed announces $10.5M private placement
Premium
The Fly
CervoMed announces $10.5M private placement
4M ago
CRVO
CervoMed announces $10.5M private placement
Premium
The Fly
CervoMed announces $10.5M private placement
4M ago
CRVO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >